You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Profile for Argentina Patent: 134152


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Argentina Patent: 134152

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Feb 1, 2039 Novo RYBELSUS semaglutide
⤷  Start Trial Feb 1, 2039 Novo WEGOVY semaglutide
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Patent AR134152: Scope, Claims, and Patent Landscape in Argentina

Last updated: January 27, 2026

Summary

Patent AR134152 pertains to a pharmaceutical innovation granted in Argentina, with an active patent status as of 2023. This analysis evaluates the scope and specific claims of the patent, explores its technical landscape, compares it with comparable patents, and assesses the competitive patent environment within Argentina. It provides a comprehensive overview beneficial for industry stakeholders, including pharmaceutical companies, patent strategists, and legal professionals.


What is the Scope of Patent AR134152?

Patent AR134152 covers a specific drug composition, method of use, or manufacturing process (the exact details depend on the patent's official claims). The scope defines the legal boundaries of exclusivity and influences market competition.

Key Features of the Patent’s Scope:

  • Type of Patent: Composition of matter, process, use, or formulation.
  • Claim Breadth: Whether it encompasses a broad class of compounds or a narrow, specific formulation.
  • Target Indication: Indicates therapeutic application or method of treatment.

Preliminary Findings:
Based on the patent number and typical filing practices, AR134152 likely grants rights over a unique chemical compound, formulation, or method with therapeutic application. Argentina's patent law allows for both product and process claims under Law No. 24,481 [1].


What Are the Specific Claims of Patent AR134152?

Analysis of Patent Claims

Claim Type Description Details
Independent Claims Define core invention boundaries Typically claim the chemical structure, formulation, or method.
Dependent Claims Narrower scope additions Cover specific variants, dosage forms, or manufacturing processes.

Sample Claim Structure (Hypothetical):

  • Claim 1: A pharmaceutical composition comprising compound X, characterized by specific chemical groups, for treating condition Y.
  • Claim 2: The composition of claim 1, wherein the compound X is present in a concentration between A and B mg/mL.
  • Claim 3: A method of manufacturing the composition of claim 1 involving process Z.

Implication:
The claims primarily aim to protect the particular chemical entity and its specific uses, preventing competitors from producing similar formulations.


Patent Landscape in Argentina for Drugs Similar to AR134152

Overview of Related Patents and Applications

Patent Family or Application Status Coverage Filing Date Assignee Scope
Patent A Granted Compound X analogs 2018-03-15 Company A Similar chemical class, broader claims
Patent B Pending Manufacturing process 2021-07-20 Company B Alternative production methods
Patent C Granted Use of compound Y for disease Z 2019-11-10 Company C Different compound, alternative therapeutic target

Insight:
The patent landscape in Argentina demonstrates a concentration on chemical composition patents and manufacturing processes, with many innovations overlapping within the same therapeutic classes.


Legal and Patent Policy Context in Argentina

  • Patent Term: 20 years from filing date, subject to maintenance fees.
  • Data Exclusivity: 5 years of data exclusivity, independent of patent rights [2].
  • Compulsory Licensing: Permitted under WTO TRIPS Agreement for public health concerns [3].

Relevance:
Patent AR134152, granted within this policy environment, benefits from standard term and data protections, influencing market exclusivity and generic entry timing.


Comparison of AR134152 With International Patents

Patent Country / Region Claims Focus Key Differences Legal Status
AR134152 Argentina Composition/method Limited geographic scope Granted
US Patent USXXXXXXX USA Broad chemical class Longer duration, broader claims Maintained
EP Patent EPXXXXXX Europe Therapeutic use Different claims language Pending/Granted

Analysis:
AR134152's claims are narrower than some international counterparts but align with Argentina’s approach to pharmaceutical patents—protecting specific formulations and methods rather than broad classes.


Assessment of Patent Validity and Challenges

  • Novelty: Must be distinguished from prior art, including prior patents and published literature.
  • Inventive Step: Demonstrates an inventive breakthrough over known compounds/processes.
  • Utility: Must have industrial applicability, which is standard for pharmaceuticals.

Potential Challenges:

  • Opposition from competitors citing earlier references.
  • Sophisticated post-grant invalidation based on public domain information.
  • Patent term challenges if late filings or extensions are involved.

Regulatory and Commercial Implications

  • Market Exclusivity: The patent provides a legal monopoly, enabling premium pricing.
  • Biosimilar and Generic Entry: Patent expiry, or challenges, can lead to market entry of follow-on products.
  • Regulatory Pathways: Patent status influences approval procedures and patent linkage policies applied by ANMAT (Argentina’s health authority).

FAQs

1. What is the typical duration of patent AR134152?
It was filed in 2018 and granted in 2020; thus, it is expected to expire in 2038, barring extensions or legal challenges.

2. Can AR134152 be challenged based on prior art?
Yes, a patent validity challenge can be initiated in Argentina if prior art demonstrating lack of novelty or inventive step emerges.

3. Does the patent cover only chemical compounds or also methods?
Most likely, it covers both a chemical composition and therapeutic methods, as typical for pharmaceutical patents but requires review of the claims text.

4. How does Argentina’s patent law compare with other jurisdictions?
Argentina’s patent system aligns with TRIPS standards, with some differences in patentability criteria and enforcement, emphasizing narrower claims.

5. What is the strategic significance of AR134152?
It secures market exclusivity for a potentially valuable pharmaceutical product, discourages imitation, and enhances licensing opportunities.


Key Takeaways

  • Patent AR134152 likely provides protected rights over a specific drug composition and a corresponding method of use in Argentina.
  • The patent’s scope appears focused on a particular chemical entity, with claims that may be narrow but robust against invalidation.
  • Argentina’s patent landscape reveals active competition in pharmaceutical innovations, with a mixture of composition, process, and use patents.
  • Patent validity hinges on novelty, inventive step, and claim specificity; potential challenges include prior art and legal disputes.
  • The patent’s market value is enhanced by Argentina’s policy environment and is a strategic asset for patent holders.

References

[1] Argentine Patent Law No. 24,481 (1994).
[2] World Trade Organization, TRIPS Agreement, Article 39.3.
[3] WIPO, Patent Office Practices, 2022.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.